- Home
- RCUS vs KEN Comparison
RCUS vs KEN Comparison
Compare RCUS & KEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- KEN
- Stock Information
- Founded
- RCUS 2015
- KEN 2014
- Country
- RCUS United States
- KEN Singapore
- Employees
- RCUS N/A
- KEN N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- KEN Electric Utilities: Central
- Sector
- RCUS Health Care
- KEN Utilities
- Exchange
- RCUS Nasdaq
- KEN Nasdaq
- Market Cap
- RCUS 1.4B
- KEN 1.5B
- IPO Year
- RCUS 2018
- KEN N/A
- Fundamental
- Price
- RCUS $13.81
- KEN $31.80
- Analyst Decision
- RCUS Buy
- KEN
- Analyst Count
- RCUS 12
- KEN 0
- Target Price
- RCUS $34.50
- KEN N/A
- AVG Volume (30 Days)
- RCUS 626.1K
- KEN 13.0K
- Earning Date
- RCUS 02-19-2025
- KEN 12-05-2024
- Dividend Yield
- RCUS N/A
- KEN 11.95%
- EPS Growth
- RCUS N/A
- KEN N/A
- EPS
- RCUS N/A
- KEN 3.23
- Revenue
- RCUS $263,000,000.00
- KEN $742,796,000.00
- Revenue This Year
- RCUS $127.65
- KEN N/A
- Revenue Next Year
- RCUS N/A
- KEN N/A
- P/E Ratio
- RCUS N/A
- KEN $9.80
- Revenue Growth
- RCUS 119.17
- KEN 8.29
- 52 Week Low
- RCUS $13.51
- KEN $19.63
- 52 Week High
- RCUS $20.31
- KEN $34.33
- Technical
- Relative Strength Index (RSI)
- RCUS 33.05
- KEN 55.68
- Support Level
- RCUS $13.51
- KEN $31.30
- Resistance Level
- RCUS $15.62
- KEN $32.37
- Average True Range (ATR)
- RCUS 0.60
- KEN 0.92
- MACD
- RCUS -0.16
- KEN -0.03
- Stochastic Oscillator
- RCUS 11.67
- KEN 48.81
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About KEN Kenon Holdings Ltd.
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented, businesses. The company's operating segments include OPC; CPV Group; and ZIM. It generates maximum revenue from the OPC segment. OPC operates in the Israeli electricity generation sector, including initiating, developing, constructing, and operating power plants and selling and supplying electricity. Geographically, it derives a majority of its revenue from Israel.